Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasiti...(the spread of leishmaniasisto U.S. troop...),Health

Date:8/27/2007

the spread of leishmaniasis to U.S. troops and contractors in Iraq and Afghanistan. Upstream also intends to begin screening compounds against malaria shortly and to test compounds from related classes as potential therapies for tuberculosis. The millions of individuals affected by these two diseases are increasingly infected with multiple drug resistant strains, highlighting the need for new therapies.

Mr. Bellenson continued, "These parasitic diseases take an enormous personal, social and economic toll on communities in the developing world, affecting millions of individuals and also decimating the cattle herds that are an integral part of rural economies. We believe the growing interest in addressing global health issues makes this an ideal time to pursue new drugs for these devastating conditions, and we intend to work collaboratively with a variety of public and private organizations to ensure the timely and cost effective clinical development of drug candidates generated by our new technology platform. We also expect to pursue other therapeutic applications of this potentially powerful drug discovery technology going forward."

Pacific Pharma's proprietary technology platform takes existing compounds that have demonstrated efficacy against the target disease and uses artificial intelligence, computer simulation and pattern recognition techniques to identify key structural elements associated with their efficacy. Screening analyses and diversity generation chemistry are then applied to produce an array of potential drug candidates. The technology can also be used to identify novel applications for existing drugs. It was developed by Artem Cherkasov, Ph.D., a faculty member in the Department of Infectious Diseases in the Faculty of Medicine at the University of British Columbia. At the annual meeting of the American Chemical Society in Boston last week, Dr. Cherkasov gave a scientific presentation describing how this technology may be effective for t
'/>"/>

SOURCE Upstream Biosciences Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials